In patients with BRCA1/2 deficient cancers, one such approach has been to develop molecular targeted therapy using PARP inhibitors that selectively exploit biological pathways within tumour cells, which differ from those in normal cells and wider concepts of genetic synthetic lethality [4–6]. Here, BRCA1 is linked to neoplasm.